Biblio
Dual-targeting CD33/CD123 NANOBODY® T cell engager with potent anti-AML activity and good safety profile. Blood Adv. 2024.
Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020.
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. Acta Haematol. 2019:1-9.
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015.
Targeting hypoxia in the leukemia microenvironment. Int J Hematol Oncol. 2013;2(4):279-288.
.